CPC
NBIX icon

Cookson Peirce & Co’s Neurocrine Biosciences NBIX Stock Holding History

Cookson Peirce & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-107,271
Closed -$15.2M – 341
2025
Q4 		$15.2M Buy
+107,271
New +$15.5M 0.63% 46
2024
Q4 		– Sell
-2,017
Closed -$232K – 291
2024
Q3 		$232K Sell
2,017
-13,037
-87% -$1.79M 0.01% 235
2024
Q2 		$2.07M Sell
15,054
-67
-0.4% -$9.19K 0.1% 80
2024
Q1 		$2.08M Buy
15,121
+3,932
+35% +$537K 0.11% 77
2023
Q4 		$1.47M Sell
11,189
-305
-3% -$35.1K 0.09% 86
2023
Q3 		$1.29M Buy
+11,494
New +$1.21M 0.08% 96
2023
Q1 		– Sell
-11,025
Closed -$1.32M – 245
2022
Q4 		$1.32M Sell
11,025
-379
-3% -$44.4K 0.09% 89
2022
Q3 		$1.21M Buy
+11,404
New +$1.16M 0.09% 94
2020
Q1 		– Sell
-12,023
Closed -$1.29M – 159
2019
Q4 		$1.29M Buy
12,023
+6,193
+106% +$648K 0.11% 85
2019
Q3 		$525K Buy
+5,830
New +$545K 0.05% 115

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cookson Peirce & Co's NBIX Position: Q1 2026 in Review

Cookson Peirce & Co sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 107,271 shares — an estimated $15.2M sold.

Cookson Peirce & Co first reported a position in NBIX in Q3 2019 and held it in 10 quarters. The position peaked at $15.2M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Cookson Peirce & Co reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Cookson Peirce & Co sold 107,271 Neurocrine Biosciences shares in Q1 2026, an estimated $15.2M.
  • Cookson Peirce & Co first reported a position in Neurocrine Biosciences in Q3 2019 and held it in 10 quarters.
  • Cookson Peirce & Co's Neurocrine Biosciences position peaked at $15.2M in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Cookson Peirce & Co's 13F filing for Q1 2026, filed 30 Apr 2026.